Hydroxyurea Medac (Hydroxycarbamide)

Hydroxycarbamide blocks ribonucleotide reductase, an enzyme needed to make deoxyribonucleotides for DNA synthesis. By depleting these building blocks, the drug halts DNA replication in rapidly dividing cells, which reduces the overproduction of abnormal blood cells seen in its approved indications.

The dosage of Hydroxyurea Medac is individualized. A qualified prescriber determines the appropriate amount based on the patient’s condition, laboratory values, and response to therapy. No fixed regimen is provided here; dosing decisions must follow the prescribing information and clinical judgment.

Hydroxyurea is classified as having an unknown pregnancy category, and potential risks to the fetus or infant are not fully established. It is generally avoided in pregnancy and lactation unless the benefits clearly outweigh the risks, and the decision should be made by a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Hydroxyurea is an oral, low‑cost option that directly reduces abnormal cell proliferation, whereas alternatives such as interferon‑alpha, ruxolitinib or intensive chemotherapy may require injections, have different side‑effect profiles, or be more expensive. Choice of therapy depends on disease severity, patient tolerance, and physician assessment.

Hydroxyurea Medac should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain stability and potency throughout its shelf life.

The medication is taken orally as a tablet with a full glass of water. It can be taken with or without food, but consistency with meals may help reduce gastrointestinal discomfort. Patients should follow the prescriber’s instructions regarding timing and any necessary fasting.

The most critical risks include severe bone‑marrow suppression leading to aplastic anemia, renal toxicity, hepatic injury, and rare severe skin reactions such as Stevens‑Johnson syndrome. Regular monitoring of blood counts, kidney and liver function is essential to detect these complications early.

Hydroxyurea should be avoided in individuals with known hypersensitivity to the drug, those with pre‑existing severe bone‑marrow failure, uncontrolled infections, or severe renal/hepatic impairment. Pregnant or breastfeeding women should only use it if a specialist determines that the therapeutic benefit outweighs potential risks.